Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

terminated117%
unknown117%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

NCT00824135
completedphase_1

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

NCT00202917
terminatedphase_1

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

NCT00091611
completedphase_2

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

NCT00080353
completedphase_2

Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome

NCT01205087
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00824135Phase 1

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Completed
NCT00202917Phase 1

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

Completed
NCT00091611Phase 1

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Terminated
NCT00080353Phase 2

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

Completed
NCT01205087Phase 2

Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome

Completed
NCT00619372Phase 1

Oral OKT3 in Combination With Beta-D-Glucosylceramide

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6